NON CLEAR CELL RCC IN TEMSIROLIMUS PIVOTAL TRIAL (ARCC)
Overall Survival
‐
INF‐α
Temsirolimus
Temsirolimus vs INF‐α
Median (mo, 95% CI)
Median (mo, 95% CI)
HR (95% CI)
ccRCC
8.2 (6.6 – 10.4)
10.7 (8.5 – 13.0)
0.82 (0.64 – 1.06)
nccRCC
4.3 (3.2 – 7.3)
11.6 (8.9 – 14.5)
0.49 (0.29 – 0.85)
Progression‐free Survival
INF‐α
Temsirolimus
Temsirolimus vs INF‐α
Median (mo, 95% CI)
Median (mo, 95% CI)
HR (95% CI)
ccRCC
3.7 (2.5 – 4.6)
5.5 (3.8, 7.1)
0.76 (0.60 – 0.97)
nccRCC
1 8 (1 6 2 1)
7 0 (3 9 8 9)
0 38 (0 23 0 62)
66
Hudes G et, al. N Engl J Med 2007;356:2271‐81
Dutcher JP, et al. Med Oncol 2009;26:202‐9
. . – .
. . – .
. . – .
